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Impact of Induction Chemotherapy on Estimated Risk of
Radiation Pneumonitis in Small Cell Lung Cancer
Neha P. Amin, MD,* Moyed Miften, PhD,* Brian Kavanagh, MD,* David Raben, MD,*
D. Ross Camidge, MD, PhD,† Dale Thornton, RTT, CMD,* Nicole Rochford, BS,*
and Laurie E. Gaspar, MD, MBA*
Introduction: Induction chemotherapy in patients with bulky small
cell lung cancer (SCLC) could lead to decreased tumor burden,
smaller radiation fields, and less pulmonary toxicity. This study
compared radiation therapy (RT) plans based on pre- and postche-
motherapy computed tomography (CT) scans of patients with SCLC
to estimate the reduced risk of radiation pneumonitis (RP) after
receiving chemotherapy.
Methods: Between 2003 and 2009, 23 patients with stage IV SCLC
were treated with chemotherapy alone (no surgery or RT) and had
computed tomography scans pre- and post two cycles of platin-
based chemotherapy. Simulated RT plans were created as if to
deliver 45 Gy to the thoracic disease. The percent of lung receiving
20 Gy (V20), mean lung dose, and normal tissue complication
probability (NTCP) was evaluated in patients who had a partial
response (30% volumetric reduction) in gross tumor volume.
Results: One (4.3%) patient had a complete response, 18 (78.3%)
had a partial response, and four (17.4%) had stable disease. Among
18 responders, the absolute decrease in V20 was 7.4% (p  0.01),
in mean lung dose was 3.3 Gy (p  0.01), and in NTCP was 5.5%
(p 0.01). Patients with a prechemotherapy V2035% versus V20
less than 35% had an average absolute reduction in NTCP of 10%
versus 2% (p  0.01).
Conclusion: Patients with limited stage SCLC with a V20 35%
may benefit from induction chemotherapy as there is an estimated
reduction of RP of 10%. This reduction in risk of RP after induction
chemotherapy should be weighed against risks and benefits of
delaying upfront RT.
Key Words: Radiation pneumonitis, Small cell lung cancer, Che-
motherapy response.
(J Thorac Oncol. 2011;6: 1553–1562)
An estimated 223,520 people in the United States will bediagnosed with lung cancer in 2010,1 of which 15 to 25%
will be small cell lung cancer (SCLC) histology. Patients with
SCLC can be staged using the TNM staging system, but in
practice, these tumors are divided into those with limited
(LSCLC) versus extensive (ESCLC) stage disease2 based on
a simple staging system developed by the Veterans Admin-
istration Lung Study Group in 1957 for randomized trials in
inoperable patient with lung cancer.3 Approximately one
third of patients will present with LSCLC.4 LSCLC is defined
as disease confined to the thorax that can be included in a
“tolerable” radiation field, whereas extensive stage patients
often have extrathoracic metastases.3
Although early thoracic radiation therapy (TRT) with
chemotherapy has been found to have a survival benefit in
some trials,5–7 yet not in others,8–12 the standard treatment for
patients with LSCLC can still be considered chemotherapy
with TRT starting day 1 of the first cycle of chemother-
apy.13–15 In patients with bulky tumors, this can lead to a
large volume of normal lung receiving radiation, often in-
creasing the chance of treatment-related radiation pneumoni-
tis (RP). Previous studies have shown that the volume of
normal lung receiving 20 Gy (V20), mean lung dose
(MLD), and location of tumor are predictive factors for
developing clinically evident (grades 2–3) pneumonitis.16–19
Therefore, some parameters that have been used to define a
“tolerable” radiation field include V20 and MLD.
An alternative is to treat patients with LSCLC with
induction chemotherapy followed by concurrent chemoradia-
tion therapy. When cisplatin-containing regimens are used in
ESCLC, the overall response rate by RECIST is approxi-
mately 40 to 70%,20,21 and complete response (CR) rate is
estimated at 10 to 20%. So we hypothesized that induction
chemotherapy for LSCLC would allow time for tumor re-
sponse that could lead to smaller radiation fields that would
allow for decreased V20 and MLD, decreased incidence of
pulmonary toxicity, and the ability to allow for higher doses
of radiation to maximize the probability of local control.22,23
Currently, there is limited information about the effect of
induction chemotherapy on the volume of normal lung sub-
sequently irradiated, i.e., the volume of normal lung that can
be spared by allowing for tumor response to induction che-
motherapy.
The objective of this study was to estimate the reduc-
tion in risk of pneumonitis, using simulated RT plans on the
pre- and post two cycles of chemotherapy computed tomog-
raphy (CT) scans in patients with ESCLC who did not get
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thoracic radiation or resection, by measuring the change in
V20, MLD, clinical target volume (CTV), and normal tissue
complication probability (NTCP).
PATIENTS AND METHODS
A retrospective review of consecutive patients identi-
fied by the Tumor Registry at the University of Colorado
from 2003 to 2009 identified 23 patients with ESCLC who
received chemotherapy (no surgical resection or radiation)
and had pre and postchemotherapy diagnostic CT scans. Two
cycles of chemotherapy were given between the CT scans.
Patients with pleural effusions were excluded.
The XIO Radiation planning system (Elekta CMS, St.
Louis, MO) was the treatment planning system used to
measure the volumetric changes in gross tumor volume
(GTV) and to create simulated radiation plans on diagnostic
CT scans performed pre- and post two cycles of chemother-
apy. Plans were only made for patients who had a volumetric
decrease of GTV 30% or partial response (PR). The defi-
nitions for response that were used include a complete re-
sponder (CR) had no residual tumor, partial responder had
30% decrease in GTV, a patient with progressive disease
had 24% increase in GTV, and stable disease was de-
fined as less than 30% reduction and less than 24%
increase in GTV.24
Critical structure dose constraints were defined using the
definitions from the CALGB 30610/RTOG 0538 protocol25 (Table
1). The target volumes are summarized in Table 2. CTV was
defined as GTV plus elective nodal coverage of the ipsilateral
hilum and subcarina. The planning target volume (PTV) was
created after a 1.5 cm expansion in the superior and inferior
direction and a 1 cm expansion axially. Differentiating tumor
from atelectasis is always an issue. A senior radiation oncol-
ogist reviewed all volumes, and IV contrast-enhanced CT
scans helped distinguish tumor from atelectasis. Positron
emission tomography scans were not routinely available to
help delineate tumor volumes from atelectasis. For each
patient, a three-dimensional plan (3D) was first generated. If
the 3D plan did not satisfy the constraints, an intensity
modulated radiation therapy (IMRT) plan was generated. The
same type of plan (i.e., 3D or IMRT) was created using the
pre- and postchemotherapy CT scans with similar beam
angles and beam energies. As the CT scans used were
diagnostic scans, they often had portions of the skin cutoff
near the shoulder regions. This cutoff portion was treated as
the patient’s skin as it was not possible to draw in skin. The
density correction for contrast was also used for the diagnos-
tic scans that used contrast. Dose calculations with inhomo-
geneity corrections for lung were performed. All plans had a
minimum of 95% of the PTV receiving the prescription dose.
A dose-volume histogram was created to measure and com-
pare the doses to organs at risk (spinal cord, heart, esophagus,
and normal lung) and the following parameters between pre-
and postchemotherapy RT plans: lung V20, MLD, GTV,
CTV, and PTV.
The Lyman-Kutcher-Burman (LKB) NTCP model26,27
was used to predict the risk of RP, the end point for lung
normal tissue toxicity to irradiation. The NTCP was calcu-
lated using the tools provided in the treatment planning
system. The NTCP model uses the following information to
estimate the incidence of normal tissue complication: dose-
volume histogram data of the irradiated normal structures,
tolerance dose for these structures, fitted parameters describ-
ing slope of the NTCP curve, and fractional volume depen-
dence for organs. The parameters needed to calculate NTCP
included the anatomical structure, TD50 (Gy), n (volume
dependency of the organ), and m (slope of the NTCP
curve). Values of TD50  31.4 Gy, n  1, and m  0.45
were used based on the recent QUANTEC recommenda-
tions for lung tissue.28
The Bradley nomogram17 is another model that esti-
mates the probability of pneumonitis, or NTCP, by using the
MLD and the center of mass (COM) of the GTV. We also
used the Bradley nomogram17 to predict the probability of
pneumonitis. The superior/inferior location of tumor within
lung was calculated by extrapolating from methods described
by Bradley et al. As only the superior/inferior location was
found to be predictive of pneumonitis, this is the only dimen-
TABLE 1. Critical Structure Dose Constraints from the
CALGB 30610/RTOG 0538 Protocol
Critical
Structure Dose Constraint
Spinal cord Total “direct”  “scatter” max dose 41 Gy
Lung ● Volume of bilateral lung minus CTV receiving 20
Gy (V20) 40%
● Mean lung dose (MLD) 20 Gy
Esophagus Mean dose 34 Gy if possible (not absolute constraint)
Heart 60 Gy to 1/3, 45 Gy to 2/3, 40 Gy to 100% of the
heart
CTV, clinical target volume.
TABLE 2. Treatment Volume Definitions Based on CALGB 30610/RTOG 0538 Protocol
Target Volumes Definition
Gross tumor volume (GTV) Volume occupied by visible or palpable disease as seen on CT/MRI, FDG-PET imaging, or biopsy-positive
sites.
Clinical target volume (CTV) GTV plus any sites that warrant irradiation because of potential occult tumor involvement, including
ipsilateral hilum (level 10), subcarinal disease (level 7). No elective treatment of supraclavicular fossae
or bilateral mediastinal lymph nodes (levels 3, 4R, 4L, 5, and 6).
Planning target volume (PTV): standard CT
simulation without 4DCT
CTV plus 1.5 cm (superior-inferior direction) and 1.0 cm (axial) margin added in to compensate for
variability in treatment setup, breathing, and motion during treatment.
CT, computed tomography; MRI, magnetic resonance imaging; FDG, fluorodeoxyglucose; PET, positron emission tomography.
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sion calculated. The entire length of the lung was first
measured and normalized to continuous values ranging from
0 to 1 inferior-to-superior direction. The center of the GTV
along the superior-inferior axis within the lung parenchyma
was then measured and assigned a value between 0 and 1
(with 1 being the most superior location and 0.5 being
midlung). Locations were separated into upper (0.75), mid-
dle (0.5–0.75), and lower (0.5) lung. The MLD calculated
from the pre- and postchemotherapy plans, along with the
upper, middle, or lower location of the tumor, was used to
predict the probability of pneumonitis using the Bradley
nomogram.
RESULTS
Patient characteristics are summarized in Table 3.
Among the total 23 patients, 19 (82.3%) patients were defined
as responders as they had a CR or PR, defined as 30%
reduction in volumetric CTV, after two cycles of platin-based
chemotherapy. Only one (4.3%) patient had a CR; however,
because of the patient’s complication of a broncho-pleural
fistula, simulated radiation plans were not made for this
patient. Four (17.4%) other patients had stable disease and,
therefore, were not analyzed further with simulated radiation
plans. The response data are summarized in Table 4, and the
absolute and relative decrease in CTV of all 23 patients is
shown in Figure 1.
Among the 18 responders for whom pre- and
postchemo RT plans were created, the mean prechemo-
therapy, postchemotherapy, absolute decrease, and relative
decrease were measured for the CTV, V20, MLD, and NTCP.
The mean CTV decreased from 338.3 ml (88.1–1570 ml) to
85.7 ml (5.95–354.2 ml) reflecting a 252.5 ml (18.9–1384.5
ml) absolute decrease or a 70% (30–93%) relative reduction
in tumor and elective lymph node burden. The mean lung
V20 decreased from 33.9% (17.7–70.6%) to 26.5% (16.7–
36.5%) reflecting a 7.4% (6.6 to 34%, p  0.01) absolute
decrease or a 17% (37 to 54%) relative reduction in V20.
The MLD decreased from 17.1 Gy (11.5–29.2 Gy) to 13.8 Gy
(10.4–19.3 Gy) reflecting a 3.3 Gy (0.13 to 12.1 Gy, p 
0.01) absolute decrease or an 18% (1 to 43%) relative
reduction in MLD. The mean lung NTCP decreased from
16.5% (6.98–44%) to 11% (6.1–19.7%) reflecting a 5.5%
(0.1 to 28.5%, p  0.01) absolute decrease or a 28% (1
to 65%) relative reduction in NTCP. The absolute estimated
risk of pneumonitis  grade 2 was decreased by 5% in
seven (30%) patients and by 10% in two (8.7%) patients,
whereas the relative risk was decreased by 20% in 13
(57%) patients and by 30% in eight (34.8%) patients.
Figure 2 graphically shows the absolute and relative change
in NTCP for the 18 patients in whom RT plans were created.
Patients 1 to 4 did not have 30% volumetric reduction, and
patient 23 had a CR, but because of a broncho-pleural fistula
in his postchemotherapy scan, we did not create RT plans for
that patient. Table 5 presents a summary of data.
A representative case of the benefit from two cycles of
chemotherapy can be seen in patient 5 displayed in Figure 3.
This patient would not have been a good candidate for
radiation at the time of diagnosis given the anticipated high
risk of RP. Nevertheless, the plan based on the postchemo-
therapy scan offered a safer RT plan.
The absolute and relative decrease in V20 and NTCP
after two cycles of chemotherapy was greater for patients
with a higher prechemotherapy V20 (Table 6). Using
SWOG0023 trial’s observation that there was a correlation of
V20 more than 35% with significant treatment-related pneu-
monitis, we grouped our patients using V20 35% as a
cutoff. For patients with a prechemotherapy V20 35%, the
NTCP was decreased by 10%, whereas for patients with V20
less than 35%, the absolute reduction in NTCP was only 2%
(p  0.01). These results maintained significance even when
an outlier patient with a prechemotherapy V20 of 70% was
removed from the analysis. It is also important to notice that
although the prechemotherapy V20, MLD, and NTCP were
significantly different between the two groups of patients
with V20 more than or less than 35%, after two cycles of
chemotherapy this difference was no longer significant.
As depicted earlier (Figure 1), there was a significant
response in CTV to chemotherapy. Although the average
prechemotherapy CTV of the patients with prechemotherapy
V20 more than 35% was almost double the average CTV in
patients with a prechemotherapy V20 less than 35%, this was
not statistically significant (Table 6). Although one would
TABLE 3. Patient Characteristics
Age (n  23)
Median (yr) 64
Range (yr) 46–83
65 yr (%) 61% (14/23)
65 yr (%) 39% (9/23)
Sex
Male 65% (15/23)
Female 35% (8/23)
Chemotherapy
Carboplatin/etoposide 52% (12/23)
Cisplatin/etoposide 22% (5/23)
Carboplatin/irinotecan 17% (4/23)
Cisplatin/etoposide  carboplatin/etoposide 4% (1/23)
Carboplatin/paclitaxel 4% (1/23)
Center of mass (COM)
Upper 13% (3/23)
Middle 43% (11/23)
Lower 39% (9/23)
TABLE 4. Tumor Response to Two Cycles of Chemotherapy
Total no. of patients 23
Complete response 1 (4.3%)
Partial response 18 (78.3%)
Stable 4 (17.4%)
Progressed 0
Response data for all 23 patients. Partial response is defined as a volumetric
decrease in gross tumor volume (GTV) of 30%. Stable disease was defined as 30%
reduction and 24% increase in GTV, whereas progression was 24% increase in
GTV.
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expect a larger CTV to correlate to a larger lung V20, there
are times when a low tumor burden also results in higher V20
values. This is mainly due to a peripheral tumor location as
there is a larger volume of normal lung that receives radia-
tion. As displayed in Figure 4, patient 14 had a prechemo-
therapy CTV of 88.1 ml (which was the second to lowest
among all the patients in this study), but the V20 was 36.4%
(7th highest V20). The tumor was located along the left
posterior peripheral lung. After two cycles of carboplatin and
etoposide, the CTV decreased by 74% from 88.1 to 22.8 ml
and the V20 decreased by 20% from 36.4 to 29.1%. This
example reiterates that both the tumor burden and location of
the tumor affect V20.
In keeping with the Bradley nomogram, the probability
of pneumonitis, or NTCP, for tumors located in the lower
lung not only had a high initial risk but also had a greater
degree of improvement in NTCP, when compared with tu-
mors in the middle or upper lung (Table 7). The Bradley
FIGURE 1. A, Absolute change in
clinical target volumes (CTV) and
(B) relative change in CTV (ml) be-
tween pre- and post two cycles of
chemotherapy computed tomogra-
phy (CT) scans for all 23 patients.
FIGURE 2. A, Absolute change in
normal tissue complication probability
(NTCP) and (B) relative change in
NTCP (%) between prechemotherapy
and postchemotherapy computed to-
mography (CT) scans for 18 patients
who had 30% decrease in gross tu-
mor volume (GTV) and for whom pre
and postchemotherapy simulated ra-
diation therapy plans were created.
Patients 1 to 4 did not have 30%
reduction in GTV, and patient 23 had
a complete response (CR), but be-
cause of postchemotherapy broncho-
pleural fistula, RT plans were not cre-
ated.
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nomogram NTCP was improved by 10% in the lower lung
tumors compared with 3% in the middle and upper lung
tumors (p  0.04). These results were also seen when using
the LKB model for NTCP; however, the degree of absolute
improvement in NTCP was not statistically significant.
Although most of the patients who had more than
30% volumetric reduction in GTV also had an improve-
ment in V20 after two cycles of chemotherapy, Figure 5
displays patient 3 who actually had a 37% relative increase
in V20 from 17.7 to 24.3% likely due to the significant
amount of previously atelectatic lung that reinflated after
chemotherapy.
DISCUSSION
Our study found a statistically significant improvement
in the volume of normal lung receiving20 Gy (V20), MLD,
and NTCP that predicts for RP in patients with ESCLC after
two cycles of platin-based chemotherapy based on simulated
RT plans on pre and postchemotherapy CT scans.
FIGURE 3. Simulated radiation
therapy (RT) plans of patient 5 dis-
played in axial, coronal, and sagittal
views on the (A) prechemotherapy
and (B) postchemotherapy com-
puted tomography (CT) scans. This
is an example of how chemother-
apy reduced tumor volume allowed
for a safer RT plan. The percentage
of lung receiving 20 Gy (V20) de-
creased from 71 to 36%, the nor-
mal tissue complication probability
(NTCP) decreased from 44 to 16%,
and mean lung dose (MLD) de-
creased from 29 to 17 Gy as the
clinical target volume (CTV) de-
creased from 1570 to 186 ml, and
the normal lung volume increased
from 4376 to 7029 ml. Green rep-
resents 45 Gy (100% isodose), red
represents 49.5 Gy (110% isodose),
and brown represents 22.5 Gy
(50% isodose).
TABLE 5. Summary of Volumes and Radiation Parameters in Pre- and Postchemotherapy Radiation Plans for the 18 Eligible
Responders
CTV PTV MLD V20 NTCP
Mean prechemotherapy 338.3 ml (88.1–1570 ml) 971.3 ml (213.0–3413.6 ml) 17.1 Gy (11.5–29.2 Gy) 33.9% (17.7–70.6%) 16.5% (6.98–44.0%)
Mean postchemotherapy 85.7 ml (5.95–354.2 ml) 444.5 ml (129.1–1340.3 ml) 13.8 Gy (10.4–19.3 Gy) 26.5% (16.7–36.5%) 11.0% (6.1–19.7%)
Mean absolute decrease 252.5 ml (18.9–1384.5 ml) 526.8 ml (65.8–2682.5 ml) 3.3 Gy (0.13 to 12.1 Gy)
p  0.01
7.4% (6.6 to 34%)
p  0.01
5.5% (0.1 to 28.5%)
p  0.01
Mean relative decrease 70% (30 to 93%) 48% (11 to 79%) 18% (1 to 43%) 17% (37 to 54%) 28% (1 to 65%)
Data from 18 responders for whom pre- and postchemotherapy radiation plans were created, including the mean absolute decrease in clinical target volume (CTV), planning target
volume (PTV), mean lung dose (MLD), percent of lung receiving 20 Gy (V20), and predicted risk of pneumonitis as calculated by the Lyman–Kutcher–Burman (LKB) model for
normal tissue complication probability (NTCP).
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Although patients with limited SCLC are often treated
with radiation starting concurrent with the first cycle of
chemotherapy using a standard radiation schedule delivering
1.5 Gy per fraction twice a day to 45 Gy,14,29 there are
patients who present with a large amount of thoracic disease
who may initially be deemed too “extensive” to safely treat
with upfront chemoradiation.3,14 There have been several
randomized trials addressing the timing of thoracic RT; some
trials report a survival benefit,5–7 whereas others do not.8–12 A
meta-analysis analyzed these eight trials and concluded that
although there is a possible benefit of early thoracic RT on
5-year OS, more research is needed to determine the optimal
timing of chest RT, especially in relationship to type of
chemotherapy, volumes treated, and compliance (or ability to
complete treatment).30 Several of these controversies will
hopefully be addressed by the ongoing studies such as the
“Phase III Comparison of Thoracic Radiotherapy Regimens
in Patients with Limited Small Cell Lung Cancer also Re-
ceiving Cisplatin and Etoposide” (CALGB 30610/RTOG
0538)25 and the Concurrent ONce daily VErsus twice daily
RadioTherapy (CONVERT) study (C. Faivre-Finn, Christie
Hospital, Manchester, UK, personal communication). CONVERT
is a phase III study comparing 45 Gy twice daily with 66 Gy
daily to known disease only (no elective nodal irradiation),
starting with the second cycle of four to six cycles of cisplatin-
etoposide chemotherapy. CALGB 30610/RTOG 0538, an inter-
group study in North America, is comparing 3 dose/fractionation
schedules with elective nodal irradiation.
The best dosimetric parameter to predict radiation-
induced lung toxicity is still not known28,31; however, previ-
ous studies have shown that in patients with non-small cell
lung cancer (NSCLC) who were treated with conventional
once daily radiotherapy, the V20, MLD, NTCP, and location
of tumor are predictive factors for developing clinically
evident (grades 2–3) pneumonitis.16–18,32–38 The Southwest
Oncology Group (SWOG) 0023 trial also observed the cor-
relation of V20 more than 35% with significant treatment-
related pneumonitis and significantly worse median survival
in NSCLC.39 Our results suggest that in patients with SCLC
in whom two cycles of chemotherapy could decrease their
volumetric tumor burden by more than 30%, the absolute risk
for RP  grade 2 can be decreased by an average of 5.5%;
approximately 30% of patients could have a 5% reduction
in NTCP, and 8 to 9% patients could have 10% reduction
in NTCP. The benefit of chemotherapy is even more pro-
nounced in those patients who would have had a prechemo-
therapy V20 more than 35%; the absolute risk of RP is
decreased by 10% compared with only 2% in patients with
prechemotherapy of V20 less than 35%.
As our study is a simulated analysis of RT plans for
patients with SCLC on their pre- and postchemotherapy
diagnostic scans, we applied information from well-estab-
lished models and parameters to estimate RP. The MLD
model was shown to correlate to both the empirical model
proposed by Kutcher and Burman27 and a radiobiological
model developed by Niemierko and Goitein40 and Jackson et
al.41 used to predict pneumonitis.36 In the Quantitative Anal-
yses of Normal Tissue Effects in the Clinic (QUANTEC)
publication on radiation dose-volume effects on the lung,28 a
logistic regression was fitted to RP versus MLD data from 10
published studies. Our results for MLD and LKB-NTCP data
fit nicely onto this logistic fit. Other studies, similar to
Bradley et al.,17 have shown that both the MLD and the
location of the tumor better predicted RP than MLD
alone.17,18 We showed that our patients with lower lung COM
tumors had a significantly higher prechemotherapy NTCP
and greater benefit from two cycles of chemotherapy than
those with middle or upper COM tumors.
Although most of the studies that have evaluated RP
and TRT were based on conventional once daily radiotherapy
in NSCLC, there were several studies that compared RP
in accelerated hyperfractionated thoracic radiotherapy
(AHFRT) to conventional once daily radiotherapy (QDRT)
for LSCLC.42–46 Tsujino et al.19 specifically studied the
relationship between lung V20 and the development of RP in
43 patients with LSCLC treated with concurrent chemother-
apy and radiation delivered at 1.5 Gy per fraction twice daily
to 45 Gy over 3 weeks, the same fractionation we used in our
simulated RT plans. Multivariate analysis, which included
multiple radiation dosimetric end points, age, forced expira-
tory volume and gender, revealed that only V20 significantly
predicted for subsequent RP  grade 2. Twelve-month cu-
mulative incidence of grade 2 or higher RP according to lung
V20 values for the AHFRT group was 0% (n 6), 7.1% (n
14), 25% (n  16), and 42.9% (n  7) in patients with a V20
of less than 20%, 21 to 25%, 26 to 30%, and more than 30%,
respectively.
TABLE 6. Comparison of Dosimetric Parameters When
Separated by Prechemotherapy V20  or 35%
V20
>35%
V20
<35% p
No. of patients 8 10
V20
Mean prechemotherapy 42% 27% 0.01
Mean postchemotherapy 29% 25% NS
Absolute reduction 14% 2% 0.01
Relative reduction 31% 6% 0.01
NTCP
Mean prechemotherapy 22% 12% 0.01
Mean postchemotherapy 12% 10% NS
Absolute reduction 10% 2% 0.01
Relative reduction 42% 17% 0.01
MLD
Mean prechemotherapy 20 Gy 15 Gy 0.01
Mean postchemotherapy 15 Gy 13 Gy NS
CTV
Mean prechemotherapy 466 ml 236 ml NS
Mean postchemotherapy 108 ml 68 ml NS
The average pre- and postchemotherapy values of the percent of lung receiving
20 Gy (V20), mean lung dose (MLD), and normal tissue complication probability
(NTCP), clinical target volume (CTV), and the absolute and relative reduction in
these parameters in patients separated into groups based on prechemotherapy V20 
or 35%.
NS, not significant.
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By applying the estimates from the findings of Tsujino
et al. on our study’s set of 18 patients with SCLC in whom
the mean lung V20 statistically significantly decreased from
34 to 27% after two cycles of induction chemotherapy, the
predicted 12-month cumulative incidence of grade 2 or higher
RP decreased from 42.9 to 25%. These estimates of RP are
more than double the estimates from the NTCP values de-
rived from the LKB model, which calculated a decrease in
NTCP from 16.5 to 11%. The upper limit of V20 in the study
by Tsujino et al. was 35%, whereas eight (44%) of our
patients had a prechemotherapy V20 greater than 35%, and
one patient continued to have a V20 more than 35% in the
postchemotherapy RT plan. It is likely that as our patients had
higher V20 values than the patients analyzed in the study by
Tsujino et al., our data points would have been skewed
toward the higher end of risk for RP.
Our data fit more closely to the the LKBmodel than to the
findings of Tsujino et al., even though the LKB model may
apply more closely to patients receiving daily fractionation than
to twice daily fractionation that is often still used in SCLC.
When Tsujino et al. compared rates of RP in patients given
QDRT versus AHFRT, the V20 values tended to be higher for
the same grade of RP in the AHFRT group than in the QDRT
group. So it is possible that the LKB model may even overes-
timate the risk of RP in patients who get twice daily RT.
There were 19 of the 23 patients (83%) who had a CR
or PR to two cycles of chemotherapy; a response rate which
FIGURE 4. Simulated radiation
therapy (RT) plans of patient 14 dis-
played in axial, coronal, and sagittal
views on the (A) prechemotherapy
and (B) postchemotherapy com-
puted tomography (CT) scans. No-
tice the amount of normal lung be-
ing irradiated due to the peripheral
location of the tumor. Green repre-
sents 45 Gy (100% isodose), red
represents 49.5 Gy (110% isodose),
and brown represents 22.5 Gy
(50% isodose).
TABLE 7. Normal Tissue Complication Probability (NTCP)
Values Derived from the Bradley Nomogram and Lyman–
Kutcher–Burman (LKB) Model
All
Patients
Lower
COM
Middle/Upper
COM p
No. of patients 18 9 9
Bradley nomogram NTCP
Mean prechemotherapy 26% 36% 16% 0.01
Mean postchemotherapy 20% 26% 13% 0.01
Absolute difference 6% 10% 3% 0.04
Relative difference 25% 27% 20% NS
LKB-NTCP
Mean prechemotherapy 17% 20% 13% 0.05
Mean postchemotherapy 11% 13% 10% 0.06
Absolute difference 6% 7% 3% NS
Relative difference 33% 37% 28% NS
The estimated risk for radiation pneumonitis in pre- and postchemotherapy scans
for the 18 patients who had 30% reduction in gross tumor volume (GTV) when
patients were separated based on the location of the center of mass (COM) of the tumor.
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is slightly higher than previously reported SCLC response
rates of 40 to 70% to induction chemotherapy.20,21,47 During
the time these patients were treated, it was the usual medical
practice at our institution to rescan after two cycles of
chemotherapy. Oncologists may consider checking tumor
response after one cycle of chemotherapy to assess whether
the tumor volumes have decreased sufficiently to start con-
current RT. This is also the study design in the CONVERT
study mentioned earlier in the text.
As there can be a large difference between prechemo-
therapy or postchemotherapy volumes, it is important to
define what volumes will be used for radiation planning
purposes. It is now standard practice to use the postchemo-
therapy volumes.14 An earlier study by Liengswangwong et
al.48 tried to determine the most appropriate volume that
should be encompassed by TRTs for patients with LSCLC
who have responded to initial chemotherapy. This retrospec-
tive study of 59 patients with SCLC found that the use of
TRT fields that encompass postchemotherapy tumor volumes
did not decrease treatment efficacy: it did not increase the risk
of marginal failures or intrathoracic failures outside the TRT
field. Nevertheless, they could not clearly depict if this
reduction in volume of irradiated normal lung decreased the
risk of developing RP. This study supports our decision to use
postchemotherapy volumes.
The decision to use elective nodal irradiation was
consistent with those used in the CALGB/RTOG protocol.25
One deviation from this protocol was that only the ipsilateral
hilum and subcarina were electively covered, whereas the
protocol asked for additional elective coverage of the ipsilat-
eral mediastinum. Although there is evidence that involved
field irradiation is just as effective as using elective cover-
age,49,50 the use of elective coverage of the ipsilateral hilum
and subcarina continues to be common clinical practice for
patients with SCLC. Elective coverage of lymph nodes
would increase the “absolute” V20, MLD, and NTCP,
especially in the contralateral lung when trying to cover
the subcarinal region. Nevertheless, it would not necessar-
ily change the relative change, pre- and postchemotherapy,
in these parameters.
Although V20, MLD, and NTCP are often reliable
parameters with which to analyze whether a radiation plan
offers a tolerable risk of pneumonitis, there are situations
when these values may be less helpful. For example, when a
tumor compresses an airway and causes atelectasis, or col-
lapse of part of the lung, it may be difficult to determine what
FIGURE 5. Simulated radiation
therapy (RT) plans of patient 3 dis-
played in axial, coronal, and sagittal
views on the (A) prechemotherapy
and (B) postchemotherapy com-
puted tomography (CT) scans. The
left lung volume expanded from
270 to 1861 ml, whereas the per-
centage of lung receiving 20 Gy
(V20) increased 37% from 17.7 to
24.3%, likely due to the reinflation
in normal lung. Green represents 45
Gy (100% isodose), red represents
49.5 Gy (110% isodose), and
brown represents 22.5 Gy (50%
isodose).
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part of the consolidation is tumor and what part is normal
collapsed lung.51,52 If the tumor and collapsed lung are all
contoured as the CTV, then the calculations for V20, MLD,
and NTCP may have spurious results. Figure 5 displays a
prechemotherapy scan of patient 3, which shows a large
consolidation in the left lung. In the postchemotherapy scan,
the left lung largely reinflates from 270 to 1680 ml. By
relying on the V20 results alone, one would think that the
postchemotherapy RT plan resulted in a V20 that was rela-
tively 37% worse than the prechemotherapy scan. Neverthe-
less, in this case, we can clearly see that the chemotherapy
improved the patient’s scans, and the postchemotherapy scan
would be more ideal for an RT plan. The increasing use of
positron emission tomography scans may help to further
delineate tumor from atelectasis.53
In conclusion, our results suggest that patients with
LSCLC with a V20 35% had only a 2% decreased risk in
RP, indicating that starting chemoradiation immediately is
advisable. Nevertheless, patients with LSCLC with a V20
more than 35% may benefit from induction chemotherapy as
there is an estimated reduction of RP of 10%. This reduction
in risk of RP after induction chemotherapy should be weighed
against risks and benefits of delaying upfront RT.
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